4-Aminopyridine: all 61 studies that test it

Page 1 of 1. Open to participants first (12), then studies with results posted, then the rest; newest registration first within each.

• Single Dose 4-Aminopyridine for Diagnosing Recurrent Laryngeal Nerve Paralysis Continuity After TraumaNot yet recruitingNCT07832331Phase 1
• The Role of Potassium Channels in Working Memory Impairments of Chronic Cocaine UsersRecruitingNCT07532460Not applicable
• A Randomized, Parallel-arm, Double Blind, Placebo-controlled Study to Assess the Efficacy of Fampridine for Patients With Spinocerebellar Ataxia SCA27B Caused by a GAA Expansion in the FGF14 GeneRecruitingNCT07185347Phase 3
• Preoperative Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal TumorRecruitingNCT07171203Phase 1
• Double Dose 4-AP on Functional Recovery After Spinal Cord InjuryRecruitingNCT06853015Phase 1/2
• Cross-over Study on the Influence of Fampridine on Working Memory in Mild to Moderate DepressionRecruitingNCT06751784Phase 2
• 4-Aminopyridine to Treat Skin BurnsRecruitingNCT06596434Phase 2
• 4-aminopyridine for Skin Wound HealingRecruitingNCT06333171Phase 2
• 4AP for Carpal Tunnel Syndrome (CTS)Not yet recruitingNCT06294821Phase 2
• Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple SclerosisRecruitingNCT06136728Phase 3
• 4-AP Peripheral Nerve Crossover TrialRecruitingNCT06003166Phase 2
• 4-aminopyridine Treatment for Nerve InjuryRecruitingNCT03701581Phase 2/3
• A Single Dose Pharmaco-Diagnostic for Peripheral Nerve Continuity After TraumaTerminatedNCT04026568Phase 2/3Results posted
• Effect of Dalfampridine (4-AP) on Genioglossus Muscle Activity in Healthy AdultsCompletedNCT02656160Phase 2Results posted
• Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Dalfampridine.TerminatedNCT02422940Phase 3Results posted
• Study and Treatment of Visual Dysfunction and Motor Fatigue in Multiple SclerosisCompletedNCT02391961Phase 2Results posted
• Efficacy and Safety of 4-aminopyridine on Cognitive Performance and Motor Function of Patients With Multiple SclerosisCompletedNCT02280096Phase 2Results posted
• A Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets.CompletedNCT02271217Phase 3Results posted
• Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple SclerosisCompletedNCT02219932Phase 3Results posted
• A Study of the Effectiveness of Fampridine in Improving Upper Limb Function in MSCompletedNCT02208050Phase 4Results posted
• Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch)CompletedNCT02166346Phase 2Results posted
• Effects of Dalfampridine on Cognition in Multiple SclerosisCompletedNCT02006160Phase 2/3Results posted
• Dalfampridine and Gait in Spinocerebellar AtaxiasCompletedNCT01811706Not applicableResults posted
• Safety and Efficacy of Oral Fampridine-Sustained Release (SR) for the Treatment of Spasticity Resulting From Spinal Cord InjuryCompletedNCT01683838Phase 3Results posted
• Short and Long Term Treatment With 4-AP in Ambulatory SMA PatientsCompletedNCT01645787Phase 2/3Results posted
• Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple SclerosisCompletedNCT01480076Phase 4Results posted
• Dalfampridine for Imbalance in Multiple SclerosisCompletedNCT01444300Phase 2Results posted
• A Placebo Controlled Trial of Dalfampridine ER for Ambulatory Activity in People With Multiple SclerosisCompletedNCT01356940Phase 4Results posted
• Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple SclerosisCompletedNCT00654927Phase 3Results posted
• Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis Who Participated in the MS-F204 TrialCompletedNCT00649792Phase 3Results posted
• Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR Tablets in Multiple Sclerosis Patients Who Participated in the MS-F203 TrialCompletedNCT00648908Phase 3Results posted
• Study of Fampridine-SR Tablets in Multiple Sclerosis PatientsCompletedNCT00483652Phase 3Results posted
• Study of Oral Fampridine-SR in Multiple SclerosisCompletedNCT00127530Phase 3Results posted
• Safety and Efficacy Study of Oral Fampridine-SR in Patients With Multiple SclerosisCompletedNCT00053417Phase 2Results posted
• Safety and Efficacy of Oral Fampridine-SR for the Treatment of Spasticity Resulting From Spinal Cord InjuryCompletedNCT00041717Phase 3Results posted
• Dalfampridine in Egyptian Patients With Multiple SclerosisStatus unknownNCT05730738Not applicable
• Effect of Dalfampridine in Patients With Hereditary Spastic ParaplegiaCompletedNCT05613114Not applicable
• Effects of 4-AP on Functional SCI RecoveryCompletedNCT05447676Early Phase 1
• Influence of Fampridine on Working Memory in Individuals With Post COVID-19 Condition With Subjective Cognitive ImpairmentTerminatedNCT05274477Not applicable
• Influence of Fampridine on Working Memory in Healthy Young SubjectsCompletedNCT04652557Phase 2
• Influence of Fampridine on Working Memory in Healthy SubjectsWithdrawnNCT04516603Phase 2
• Fampridine-SR and Optic Neuritis RecoveryStatus unknownNCT04148781Early Phase 1
• High Doses of 4-aminopyridine in Clinically Complete Chronic Spinal Cord Injury Patients.Status unknownNCT03899584Phase 3
• Muscle Strain in Multiple Sclerosis Patients Measured by Ultrasound Speckle Tracking TechniqueCompletedNCT03847545Not applicable
• 4-aminopyridine Treatment for Nerve Injury From Radical Retro-Pubic ProstatectomyWithdrawnNCT03658408Phase 2
• 4-Aminopyridine, Atenolol, or Placebo in Patients With Vestibular MigraineWithdrawnNCT03578354Phase 2
• Use of Dalfampridine in Primary Lateral SclerosisCompletedNCT02868567Phase 1
• Short and Long Term Multiple Outcomes in Persons With Multiple Sclerosis Treated by Fampridine.CompletedNCT02849782Phase 4
• Efficacy of Dalfampridine on Upper Extremity Function in Patients With MSStatus unknownNCT02259361Phase 4
• Prolonged-release Fampridine as Adjunct Therapy to Active Motor Training in MS PatientsCompletedNCT02146534Phase 4
• Resistance Training and Amino Pyridine in Multiple SclerosisCompletedNCT02143167Phase 4
• A New Medicine to Treat Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)CompletedNCT01975324Phase 4
• A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple SclerosisCompletedNCT01917019Phase 3
• Does Fampridine SR Improve Cognitive Fatigue in Multiple Sclerosis Patients?CompletedNCT01667497Phase 2/3
• FAME - Fampyra Outcome Measures Study: a Study of Different Outcome Measures on the Effect of FampyraCompletedNCT01656148Phase 4
• Combination Therapy With Dalfampridine and Locomotor Training for Chronic, Motor Incomplete Spinal Cord InjuryCompletedNCT01621113Phase 2
• Exploratory Study to Assess the Effect of Fampridine (BIIB041) on Walking Ability and Balance in Participants With Multiple Sclerosis.CompletedNCT01597297Phase 2
• 4-Aminopyridine in Episodic Ataxia Type 2WithdrawnNCT01543750Phase 2
• Open Label Extension Study to Evaluate the Safety and Tolerability of Oral Fampridine-Sustained Release (SR) in Canadian Participants With Multiple Sclerosis Who Participated in Acorda Extension Trials.CompletedNCT01235221Phase 3
• A Pharmacokinetics (PK) and Safety Study of Oral Fampridine-PR 10 mg in Chinese, Japanese, and Caucasian Adult Healthy VolunteersCompletedNCT01215084Phase 1
• Assessment of Chronic Guillain-Barre Syndrome Improvement With Use of 4-aminopyridineCompletedNCT00056810Phase 2

← 4-Aminopyridine overview